 | Moussa Lingani, Tomoyuki Akita, Serge Ouoba, Armel Moumini Sanou, Aya Sugiyama, Zekiba Tarnagda, Masayuki Ohisa, Halidou Tinto, Shunji Mishiro, Junko Tanaka High prevalence of hepatitis B infections in Burkina Faso (1996-2017): a systematic review with meta-analysis of epidemiological studies (Journal Article) In: BMC Public Health, vol. 18, no. 1, pp. 551, 2018, ISSN: 1471-2458. @article{Lingani2018-ex,
title = {High prevalence of hepatitis B infections in Burkina Faso (1996-2017): a systematic review with meta-analysis of epidemiological studies},
author = {Moussa Lingani and Tomoyuki Akita and Serge Ouoba and Armel Moumini Sanou and Aya Sugiyama and Zekiba Tarnagda and Masayuki Ohisa and Halidou Tinto and Shunji Mishiro and Junko Tanaka},
doi = {10.1186/s12889-018-5432-7},
issn = {1471-2458},
year = {2018},
date = {2018-04-01},
urldate = {2018-04-01},
journal = {BMC Public Health},
volume = {18},
number = {1},
pages = {551},
abstract = {BACKGROUND: Hepatitis B virus (HBV) infection was long considered
an important public health concern in Burkina Faso and still
represents a major cause of liver cancer and cirrhosis in the
active population. To counter the problem, a national strategic
plan was developed and adopted in July 2017 to coordinate viral
hepatitis elimination's efforts. However evidence to support its
implementation remains scanty and scattered. The main purpose of
this study was to summarize available information from
per-reviewed articles published over the last two decades to
accurately estimate the prevalence of HBV infection in Burkina
Faso. METHODS: We conducted a systematic search with
meta-analysis of scientific articles using Science-Direct,
Web-of-Science, PubMed/Medline, and Google Scholar. We
systematically assessed all relevant publications that measured
the prevalence of hepatitis B surface antigen and which were
published between 1996 and 2017. We estimated the national HBV
prevalence and its 95% confident interval. We subsequently
adjusted the meta-analysis to possible sources of heterogeneity.
RESULTS: We retrieved and analyzed a total of 22 full text papers
including 99,672 participants. The overall prevalence was
11.21%. The prevalence after adjustment were 9.41%, 11.11%,
11.73% and 12.61% in the general population, pregnant women,
blood donors and HIV-positive persons respectively. The
prevalence was higher before implementation of HBV universal
vaccination and decreased from 12.80% between 1996 and 2001 to
11.11% between 2012 and 2017. The prevalence was also higher in
rural area 17.35% than urban area 11.11%. The western regions
were more affected with 12.69% than the central regions 10.57%.
The prevalence was 14.66% in the boucle of Mouhoun region and
14.59 in the center-west region. Aggregate data were not
available for the other regions. CONCLUSIONS: HBV has clearly an
important burden in Burkina Faso as described by its high
prevalence and this problem significantly challenges the national
health care system. There is an urgent need for effective public
health interventions to eliminate the problem. However, higher
quality data are needed to produce reliable epidemiological
estimates that will guide control efforts towards the achievement
of the national strategic plan's goals.},
keywords = {Burkina Faso; Epidemiology; Hepatitis B; Meta-analysis; Viral infection},
pubstate = {published},
tppubtype = {article}
}
BACKGROUND: Hepatitis B virus (HBV) infection was long considered
an important public health concern in Burkina Faso and still
represents a major cause of liver cancer and cirrhosis in the
active population. To counter the problem, a national strategic
plan was developed and adopted in July 2017 to coordinate viral
hepatitis elimination’s efforts. However evidence to support its
implementation remains scanty and scattered. The main purpose of
this study was to summarize available information from
per-reviewed articles published over the last two decades to
accurately estimate the prevalence of HBV infection in Burkina
Faso. METHODS: We conducted a systematic search with
meta-analysis of scientific articles using Science-Direct,
Web-of-Science, PubMed/Medline, and Google Scholar. We
systematically assessed all relevant publications that measured
the prevalence of hepatitis B surface antigen and which were
published between 1996 and 2017. We estimated the national HBV
prevalence and its 95% confident interval. We subsequently
adjusted the meta-analysis to possible sources of heterogeneity.
RESULTS: We retrieved and analyzed a total of 22 full text papers
including 99,672 participants. The overall prevalence was
11.21%. The prevalence after adjustment were 9.41%, 11.11%,
11.73% and 12.61% in the general population, pregnant women,
blood donors and HIV-positive persons respectively. The
prevalence was higher before implementation of HBV universal
vaccination and decreased from 12.80% between 1996 and 2001 to
11.11% between 2012 and 2017. The prevalence was also higher in
rural area 17.35% than urban area 11.11%. The western regions
were more affected with 12.69% than the central regions 10.57%.
The prevalence was 14.66% in the boucle of Mouhoun region and
14.59 in the center-west region. Aggregate data were not
available for the other regions. CONCLUSIONS: HBV has clearly an
important burden in Burkina Faso as described by its high
prevalence and this problem significantly challenges the national
health care system. There is an urgent need for effective public
health interventions to eliminate the problem. However, higher
quality data are needed to produce reliable epidemiological
estimates that will guide control efforts towards the achievement
of the national strategic plan’s goals. |
